trial

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCTId NCT00982020
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 203 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2013-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
203 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2009-09
Primary completion
2013-05
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
OlanzapineStandard behavioral weight interventionIntense behavioral weight intervention

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

14 total
Lauderhill, United StatesBloomfield Hills, United StatesSt Louis, United StatesBellevue, United StatesPoznan, PolandTorun, PolandWroclaw, PolandCaguas, Puerto RicoSan Juan, Puerto RicoLipetsk, RussiaMoscow, RussiaPetrozavodsk, Russia

Facts & assertions

4 sourced
Enrollment
203
Phase
PHASE4
Primary Completion Date
2013-05
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Standard behavioral weight intervention
drug
Intense behavioral weight intervention
drug
lead_sponsor
Eli Lilly and Company
company
indication
Mania
indication
Schizophrenia
indication
Bipolar I Disorder
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person